NZ582056A - Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation - Google Patents

Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation

Info

Publication number
NZ582056A
NZ582056A NZ582056A NZ58205608A NZ582056A NZ 582056 A NZ582056 A NZ 582056A NZ 582056 A NZ582056 A NZ 582056A NZ 58205608 A NZ58205608 A NZ 58205608A NZ 582056 A NZ582056 A NZ 582056A
Authority
NZ
New Zealand
Prior art keywords
carboxamide
indole
compounds
pyrimidin
formula
Prior art date
Application number
NZ582056A
Other languages
English (en)
Inventor
Rajagopal Bakthavatchalam
David C Ihle
Scott M Capitosti
David J Wustrow
Jun Yuan
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NZ582056A publication Critical patent/NZ582056A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ582056A 2007-08-10 2008-08-11 Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation NZ582056A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95525007P 2007-08-10 2007-08-10
PCT/US2008/072760 WO2009023623A1 (en) 2007-08-10 2008-08-11 Heteroaryl amide analogues

Publications (1)

Publication Number Publication Date
NZ582056A true NZ582056A (en) 2012-08-31

Family

ID=40351102

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ582056A NZ582056A (en) 2007-08-10 2008-08-11 Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation

Country Status (14)

Country Link
EP (1) EP2185560A4 (enExample)
JP (2) JP2010535816A (enExample)
KR (1) KR20100066422A (enExample)
CN (1) CN101778850A (enExample)
AU (1) AU2008286946B2 (enExample)
BR (1) BRPI0812594A2 (enExample)
CA (1) CA2691512A1 (enExample)
CO (1) CO6251319A2 (enExample)
EA (1) EA020332B1 (enExample)
IL (1) IL202550A0 (enExample)
NZ (1) NZ582056A (enExample)
SG (1) SG183699A1 (enExample)
UA (1) UA99729C2 (enExample)
WO (1) WO2009023623A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010237302A1 (en) * 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
WO2012110190A1 (en) * 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP3552664A1 (en) 2011-05-12 2019-10-16 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
TW201309706A (zh) 2011-07-22 2013-03-01 Actelion Pharmaceuticals Ltd 作為ｐ２ｘ７受體拮抗劑之雜環醯胺衍生物
AU2013210682B2 (en) * 2012-01-20 2017-05-25 Idorsia Pharmaceuticals Ltd Heterocyclic amide derivatives as P2X7 receptor antagonists
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
EA029644B1 (ru) * 2012-12-12 2018-04-30 Идорсиа Фармасьютиклз Лтд Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
CA2891499C (en) 2012-12-18 2021-07-06 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
ES2616114T3 (es) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Derivados de amida heterocíclica como antagonistas del receptor P2X7
JP6282017B2 (ja) * 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
EP3321266A1 (en) 2013-03-14 2018-05-16 Janssen Pharmaceutica NV P2x7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US9163020B2 (en) * 2013-07-17 2015-10-20 Global Alliance For Tb Drug Development Azaindole compounds, synthesis thereof, and methods of using the same
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CU20170007A7 (es) 2014-08-06 2017-06-05 Pfizer Compuestos de imidazopiridazina
US20180118749A1 (en) 2014-09-12 2018-05-03 Janssen Pharmaceutica Nv P2x7 modulators
AU2015315687B2 (en) 2014-09-12 2019-07-11 Janssen Pharmaceutica Nv P2X7 modulators
HUE055175T2 (hu) 2014-09-29 2021-11-29 Takeda Pharmaceuticals Co Az 1-(1-metil-1H-pirazol-4-il)-N-((1R,5S,7S)-9-metil-3-oxa-9-azabiciklo[3.3.1] nonan-7-il)-1H-indol-3-karboxamid kristályos formája
EP3233841A1 (en) 2014-12-15 2017-10-25 Merck Patent GmbH Indole and azaindoles derivatives and their use in neurodegenerative diseases
JP6462493B2 (ja) 2015-05-29 2019-01-30 株式会社デンソー 進入判定装置、進入判定方法
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
TW201819361A (zh) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物
PE20211773A1 (es) 2018-09-28 2021-09-08 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipasa
EP3856179A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica N.V. Monoacylglycerol lipase modulators
KR20220075386A (ko) 2019-09-30 2022-06-08 얀센 파마슈티카 엔.브이. 방사성 표지된 mgl pet 리간드
EP4126860A1 (en) 2020-03-26 2023-02-08 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
CN116323581B (zh) * 2020-09-22 2025-05-30 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
CN119156388A (zh) * 2022-04-15 2024-12-17 海南先声再明医药股份有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
DE2931323A1 (de) * 1979-08-02 1981-02-26 Kali Chemie Pharma Gmbh Neue n-aminoalkylindol-derivate und ihre salze
DE3131527A1 (de) * 1981-08-08 1983-02-24 Kali-Chemie Pharma Gmbh, 3000 Hannover 1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
TW229140B (enExample) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
ATE293599T1 (de) * 1997-12-24 2005-05-15 Aventis Pharma Gmbh Indolderivate als faktor xa inhibitoren
TR200102911T2 (tr) * 1999-04-09 2002-01-21 Astrazeneca Ab Adamantan türevleri.
AU770600B2 (en) * 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2002012189A1 (en) * 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
RU2315746C2 (ru) * 2001-08-09 2008-01-27 Оно Фармасьютикал Ко., Лтд. Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
JP4390704B2 (ja) * 2002-10-03 2009-12-24 エフ．ホフマン−ラ ロシュ アーゲー グルコキナーゼ（ｇｋ）活性化物質としてのインドール−３−カルボキシアミド
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
EP1578418A2 (en) * 2002-12-20 2005-09-28 Bayer HealthCare AG Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
TW200700387A (en) * 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
MX2008010671A (es) * 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.

Also Published As

Publication number Publication date
BRPI0812594A2 (pt) 2015-06-23
JP2010535816A (ja) 2010-11-25
UA99729C2 (en) 2012-09-25
EA020332B1 (ru) 2014-10-30
JP2015110566A (ja) 2015-06-18
AU2008286946B2 (en) 2013-11-21
CN101778850A (zh) 2010-07-14
EP2185560A4 (en) 2011-10-05
EA200971085A1 (ru) 2010-06-30
CA2691512A1 (en) 2009-02-19
AU2008286946A1 (en) 2009-02-19
EP2185560A1 (en) 2010-05-19
IL202550A0 (en) 2010-06-30
KR20100066422A (ko) 2010-06-17
CO6251319A2 (es) 2011-02-21
SG183699A1 (en) 2012-09-27
WO2009023623A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
NZ582056A (en) Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation
NL1026958C2 (nl) Aryl- of heteroarylamideverbindingen.
NL1028947C2 (nl) Gesubstitueerde methylaryl- of heteroarylamideverbindingen.
US10005731B2 (en) Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases
KR101507717B1 (ko) Ｐｄｅ4 억제제로서 유용한 치환된 아세토페논
CN101550114A (zh) 具有cb1拮抗、激动或部分激动活性的噻唑衍生物
NZ573832A (en) N-(4-{ 2-[4-aryl-piperazin-1-yl]ethyl} cyclohexyl)-acetamide derivatives for the treatment of neuropsychiatric disorders
NO20054206L (no) Bifenylderivater
WO2000075113A1 (en) Novel heterocyclic carboxamide derivatives
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
ATE486842T1 (de) Substituierte amide
JP2008537741A5 (enExample)
JP2005526798A (ja) 疼痛を治療するためのｖｒ−１受容体修飾因子としてのヘテロ芳香族尿素誘導体
SK4799A3 (en) Use of non-peptidic n3 antagonists for producing pharmaceutical compositions
JP5485391B2 (ja) Ｐ２ｘ７調節薬としてのジヒドロピリミドンアミド類
DE60316829D1 (de) Substituierte furoä2,3-büpyridin derivate
JP2010507664A (ja) ベンズイミダゾール化合物
JP2016528274A5 (enExample)
WO2008130616A3 (en) Diaryl morpholines as cb1 modulators
NO20082919L (no) Heteroringsubstituerte 3-alkylazetidinderivater
JP2011519845A5 (enExample)
JP2015522657A (ja) ウレア化合物および酵素阻害剤としてのそれらの使用
NZ595797A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
TWI360540B (en) Tetrahydroisoquinolylsulphonamide derivatives, the
KR102688531B1 (ko) 피리미딘 화합물

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 AUG 2015 BY SPRUSON + FERGUSON

Effective date: 20130103

LAPS Patent lapsed